Investor Relations
26 August 2022(Friday)
2022 Interim Results Announcement Webinar Invitation
Dear Investors and Analysts,
Hua Medicine (2552.HK) cordially invites you or your representative to attend the online webinar in relations to the Company’s 2022 interim results, which will be held 9:00 AM GMT+8, 26 August 2022 (Friday).
During the webinar, management will provide a review of the Company’s interim financial results in 2022, business updates, as well as address plans for the future.
Details of the webinar are as follows:
Language: | English |
Date: | 26 August 2022 (Friday) |
Time: | Login starts: 8:45AM GMT+8 |
Duration: | Approx. 45 mins (including Q&A session) |
Management: |
Dr. Li Chen, CEO, Founder, and Chief Scientific Officer |
RSVP: | Registration Link:https://icaasia.zoom.us/webinar/register/WN_1qJJAQo0QCaD19R2NEylZQ (Please register via the above link no later than 25 August 2022) |
Q&A: |
If you have any questions, please send them to huamedicine@icaasia.com before 25 August 2022 (Thursday). |
*If you are intended to attend the Chinese session (10:00AM GMT+8, 26 August), please send an email to huamedicine@icaasia.com for registration. Meeting details will be provided upon confirmation.
About Hua Medicine
Hua Medicine is an innovative drug development company found in China focused on developing novel therapies for patients worldwide with unmet medical needs. Based on global resources, Hua Medicine teams up with global highcaliber people to develop breakthrough technologies and products, which contribute a global innovation in diabetes care. Targeting on glucose sensor glucokinase, dorzagliatin, as its cornerstone product, restores glucose sensitivity in T2D patients and has completed SEED and DAWN registration trials, with its NDA accepted by the National Medical Products Administration (NMPA) in China. This first-in-class glucokinase activator has demonstrated its potential of achieving diabetes remission to help millions of diabetic patients around the world.
沪ICP备99665955号-1
沪公网安备 31011502013809号 Privacy Statement Terms of Use
